Exelixis | EXEL - Acreedores Comerciales





Acreedores Comerciales Cambio Fecha
Acadia Pharmaceuticals USD 16.33M 28.24M 2026-09
Agios Pharmaceuticals USD 19.93M 3.58M 2026-09
Akebia Therapeutics USD 7.61M 1.81M 2026-09
Amgen USD 20.83B 17.97B 2026-09
AstraZeneca USD 23.57B 679M 2026-09
Bayer EUR 6.71B 314M 2026-09
BioMarin Pharmaceutical USD 946.11M 32.44M 2026-09
Bristol-Myers Squibb USD 4.63B 470M 2026-09
Cytokinetics USD 25.96M 5.45M 2026-09
Eisai JPY 87.53B 11.64B 2026-06
Eli Lilly USD 5.79B 319M 2026-09
Exelixis USD 30.83M 8.23M 2026-09
Genmab DKK 116M 110M 2026-06
Glaxosmithkline GBP 15.63B 1.3B 2026-09
Incyte USD 235.37M 1.16B 2026-09
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
MacroGenics USD 3.44M 845K 2026-06
Merck USD 5.03B 1.2B 2026-09
Moderna USD 259M 92M 2026-09
Nektar Therapeutics USD 10.03M 744K 2026-03
Neurocrine Biosciences USD 754.1M 612.1M 2026-09
Novartis USD 4.24B 15M 2026-09
Pfizer USD 4.07B 511M 2026-09
Puma Biotechnology USD 6.39M 962K 2025-09
Sanofi EUR 23.6B 888M 2026-06
Takeda JPY 486.2B 39.41B 2026-09
Ultragenyx Pharmaceutical USD 45M 6M 2026-09
Xencor USD 6.65M 6M 2026-09